Active substance
Chlorambucil
- SFDA 4
- US FDA 1
- Health Canada 1
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LEUKERAN 2 MG. TAB. | 2 mg | Film-coated tablet · Oral use | 25 Blister | SAR 237.60 | NCE · Prescription | ASPEN PHARMA TRADING LIMITED (APTL) | Valid |
| LEUKERAN 2 MG. TAB | 2 mg | Film-coated tablet · Oral use | 25 Blister | SAR 297.00 | NCE · Prescription | ASPEN | Withdrawn by MAH · Not Marketed |
| LEUKERAN 2 MG. TAB. | 2 mg | Film-coated tablet · Oral use | 25 Tablet Container | SAR 25.85 | NCE · Prescription | GLAXOWELLCOME | Withdrawn by MAH · Not Marketed |
| LEUKERAN 5 MG. TAB. | 5 mg | Film-coated tablet · Oral use | 25 Blister | SAR 39.45 | NCE · Prescription | GLAXOWELLCOME | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); FOLLICULAR LYMPHOMA; MARGINAL ZONE LYMPHOMA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LEUKERAN | 2MG | tablet · oral | WAYLIS THERAP | Prescription | 18 Mar 1957 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| LEUKERAN | 00004626 | 2 MG | TABLET · ORAL | ASPEN PHARMACARE CANADA INC. |
WHO WHO Model List of Essential Medicines (2025)
- 8.2.1. Cytotoxic medicines · complementary
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
Oral > Solid: 2 mg tablet
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.